Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-3434 in Chronic Hepatitis B
NCT06216470Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Mar 2024
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tobevibart in Chronic Hepatitis B (CHB), sponsored by University Health Network. Started Mar 2024; status: recruiting.
02
Drugs
tobevibart
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06216470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216470.